The U.S. breast cancer screening and diagnostic market is rapidly evolving, driven by advanced imaging, artificial intelligence, and precision diagnostics. Rising incidence, dense breast tissue challenges, and updated mammography guidelines USA are fueling demand for innovative, patient-centered breast care solutions.
According to BIS Research, the U.S. breast cancer screening and diagnostic market was valued at $1,556.6 million in 2024 and is projected to reach $2,342.2 million by 2030, growing at a CAGR of 7.05% during 2024–2030.
What factors are driving growth in the U.S. breast cancer screening and diagnostic market?
Rising Breast Cancer Cases: Over 3.5 million prevalent cases in the U.S. highlight the urgent need for efficient screening solutions .
Technology Shifts: Transition from 2D mammography to digital breast tomosynthesis (DBT) improves cancer detection while reducing false positives .
Dense Breast Tissue Diagnosis: Advanced imaging such as contrast-enhanced mammography (CEM) and breast MRI diagnostics provide greater clarity in challenging cases, ensuring more accurate results.
Patient-Centered Breast Care: Healthcare providers are increasingly focusing on individualized risk stratification, ensuring screening pathways are aligned with patient needs and medical histories.
Which technologies are used for U.S. breast cancer screening and diagnostic market segmentation?
Conventional 2D Mammography – declining but still in use.
Digital Breast Tomosynthesis (DBT) – fastest-growing and dominant due to higher detection rates .
Contrast-Enhanced Mammography (CEM) – emerging as an alternative to MRI for certain patients.
Breast MRI Diagnostics – particularly effective for high-risk patients and dense breast tissue.
Ultrasound and Liquid Biopsy for Breast Cancer – gaining ground as complementary tools for accurate diagnosis .
Request A Detailed Sample on the U.S. Breast Cancer Screening and Diagnostic Market – Analysis and Forecast, 2024-2030
What are the recent developments in the U.S. breast cancer screening and diagnostic market?
August 2024: Izotropic Corporation, specializing in the commercialization of IzoView—a breast CT imaging system—announced plans to pursue a regulatory strategy in the U.S. and EU. The goal is to launch IzoView as a diagnostic device for patients with dense breast tissue, which carries a higher risk of breast cancer. This updated regulatory approach positions IzoView Breast CT as a complementary diagnostic tool alongside digital breast tomosynthesis (DBT) for patients with BI-RADS C and D breast density.
March 2024: Mammotome unveiled the LumiMARK Biopsy Site Marker, a distinctive tissue marker visible from every angle under ultrasound, mammography, and MRI, enhancing biopsy site identification.
November 2023: GE HealthCare launched the MyBreastAI Suite, an all-in-one AI platform designed to assist clinicians in breast cancer detection and improve workflow efficiency. The suite includes three iCAD AI applications: ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment, collectively supporting early detection, better patient outcomes, and operational productivity in radiology departments.
February 2023: Neodynamics partnered with Uniphar Group, a global distribution and logistics leader, to support the U.S. launch of NeoNavia, an advanced pulse biopsy system.
October 2020: FUJIFILM Medical Systems U.S.A., Inc. expanded its collaboration with Volpara Solutions, a software company focused on preventing advanced-stage breast cancer. This partnership aims to provide mammography facilities and clinicians with enhanced imaging solutions that improve image quality, streamline workflow, and accurately assess breast density.
Trending FAQ on U.S. Breast Cancer Screening and Diagnostic Market
Which technologies dominate breast cancer screening in the U.S.?
Digital mammography, digital breast tomosynthesis (DBT), breast MRI, contrast-enhanced mammography (CEM), and emerging AI-powered diagnostic platforms are the dominant technologies used in U.S. breast cancer screening and early detection.
How is AI improving breast cancer diagnostics?
AI applications enhance detection accuracy, analyze mammograms and MRIs, assess breast density, reduce false positives, and streamline radiology workflows, supporting early diagnosis and better patient outcomes in breast cancer care.
What role do liquid biopsies play in diagnostics?
Liquid biopsies enable minimally invasive cancer detection through blood samples, assisting early-stage breast cancer diagnosis, monitoring treatment response, and improving personalized patient care alongside traditional imaging methods.
Which companies dominate the breast cancer diagnostics market in the U.S.?
Koninklijke Philips N.V
Canon Inc
Planmed Oy
Siemens Healthineers AG
GE Healthcare
FUJIFILM Holdings Corporation
Hologic, Inc.
Mammotome, a Danaher Corporation company
Becton, Dickinson, and Company
Metaltronica S.p.A
Future Outlook
The U.S. breast cancer screening and diagnostic market is evolving into a multi-modality, patient-centered ecosystem. Integration of AI in breast cancer screening, adoption of liquid biopsy, and greater emphasis on personalized risk stratification will reshape detection and diagnostic pathways. While mammography guidelines in the USA continue to adapt, the central challenge will be ensuring equitable access to these cutting-edge solutions, while addressing concerns around overdiagnosis in breast cancer screening.
Click Here to Download the ToC
Conclusion
With technologies like digital breast tomosynthesis trends, liquid biopsy for breast cancer, and breast cancer risk stratification, the U.S. market is set for strong growth. Balancing early detection with concerns about overdiagnosis breast cancer screening will be key to ensuring better outcomes and equitable access.
